-
Technologies
  • Clinical trials
  • Cohort studies
Themes / Divisions

About

Our lab’s vision is to develop an interdisciplinary approach to dementia research and care. Dementia is a complex condition that crosses a number of clinical and scientific disciplines. We understand that a strong, multifaceted approach is required to make a significant impact in dementia research.

This includes having a long-term coordinated approach to research.

The focus of our lab is to:
– Improve dementia diagnosis using novel and established biomarkers
– Investigate midlife risk factors that may better inform prevention strategies
– Establish and support dementia cohorts
– Facilitate investigator-led clinical trials
– Support and develop access to dementia research for regional and rural Australians
– Investigate and address caregiver needs
– Mentor the next generation of dementia clinical researchers

Publications

Selected publications from A/Prof Rosie Watson

Eratne D, Kang MJY, Lewis C, Dang C, Malpas C, Ooi S, Brodtmann A, Darby D, Zetterberg H, Blennow K, Berk M, Dean O, Bousman C, Thomas N, Everall I, Pantelis C, Wannan C, Cicognola C, Hansson O, Janelidze S, Santillo AF, Velakoulis D, Group TMS. Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders. Journal of the Neurological Sciences. 2024;467:10.1016/j.jns.2024.123291

Pra RD, O’Brien P, Nguyen HXT, Luke J, Smith RA, Withall A, Radford K, Lavrencic LM, Watson R, Flicker L, Logiudice D. Culturally safe and ethical biomarker and genomic research with Indigenous peoples—a scoping review. BMC Global and Public Health. 2024;2(1):10.1186/s44263-024-00102-0

Dobson H, Al Maawali S, Malpas C, Santillo AF, Kang M, Todaro M, Watson R, Yassi N, Blennow K, Zetterberg H, Foster E, Neal A, Velakoulis D, O’Brien TJ, Eratne D, Kwan P. Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders. Epilepsia. 2024;65(9):10.1111/epi.18065

Holper S, Loveland P, Churilov L, Italiano D, Watson R, Yassi N. Blood Astrocyte Biomarkers in Alzheimer Disease. Neurology. 2024;103(3):10.1212/wnl.0000000000209537

Bhalala OG, Thompson J, Watson R, Yassi N. Contextualising the benefits and risks of anti‐amyloid therapy for patients with Alzheimer disease and their care team. The Medical Journal of Australia. 2024;221(2):10.5694/mja2.52359

Lange PW, Turbić A, Soh CH, Clayton‐Chubb D, Lim WK, Conyers R, Watson R, Maier AB. Melatonin does not reduce delirium severity in hospitalized older adults: Results of a randomized placebo‐controlled trial. Journal of the American Geriatrics Society. 2024;72(6):10.1111/jgs.18825

Chin KS, Churilov L, Doré V, Villemagne VL, Rowe CC, Yassi N, Watson R. Tau in dementia with Lewy bodies. Australian & New Zealand Journal of Psychiatry. 2024;58(2):10.1177/00048674231177219

Chin KS, Holper S, Loveland P, Churilov L, Yassi N, Watson R. Prevalence of cerebral microbleeds in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia: A systematic review and meta-analysis. Neurobiology of Aging. 2024;134:10.1016/j.neurobiolaging.2023.11.006

Bhalala OG, Watson R, Yassi N. Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease. International Journal of Molecular Sciences. 2024;25(2):10.3390/ijms25021231

Nguyen HXT, Bradley K, McNamara BJ, Watson R, Malay R, LoGiudice D. Risk, protective, and biomarkers of dementia in Indigenous peoples: A systematic review. Alzheimer’s & Dementia. 2024;20(1):10.1002/alz.13458

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.